Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients
BackgroundIntravenous 0.9 mg/kg recombinant tissue plasminogen activator (r-tPA) is one of the most effective treatments in acute ischemic stroke patients. Practically, the dose of r-tPA is still a topic that is constantly being discussed.MethodsFor this observational study, data were obtained from...
Main Authors: | Jiawen Yuan, Ruxing Wu, Jingyan Xiang, Jiangshan Deng, Xiaojie Zhang, Kaili Lu, Fengya Cao, Fei Zhao, Yuwu Zhao, Feng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.1007167/full |
Similar Items
-
Decision for tPA Administration, Not Response Time, Contributes Most to Variation in Thrombolysis Times Onboard Mobile Stroke Unit
by: Sajal Medha K. Akkipeddi, et al.
Published: (2023-03-01) -
Predicting 1-Hour Thrombolysis Effect of r-tPA in Patients With Acute Ischemic Stroke Using Machine Learning Algorithm
by: Bin Zhu, et al.
Published: (2022-01-01) -
Case Report: Successful Reperfusion of Pulmonary Thromboembolism Using tPA in a Cat
by: Blake Sutton, et al.
Published: (2022-04-01) -
Successful Intravenous Thrombolysis in Ischemic Stroke Caused by Tuberculous Meningitis: A Case Report
by: Xinke Peng, et al.
Published: (2021-09-01) -
Intravenous thrombolysis with 0.65 mg/kg r-tPA may be optimal for Chinese mild-to-moderate stroke
by: Yu Cui, et al.
Published: (2022-09-01)